Clinical Trials Browser

Interventional × Breast Neoplasms × Fluorouracil × Clear all

NCT07318805 2026-05-08

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

BreastGastrointestinal

Breast Neoplasms, Colonic Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT00433420 2026-04-30

Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer

Phase 3 Active not recruiting

Breast Neoplasms

NCT00872625 2026-04-23

Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast Cancer

Phase 1 Completed

Breast Neoplasms

NCT02688803 2025-12-04

OTT15-04

Phase 4 Terminated

2 enrolled 4 charts

Breast Neoplasms

NCT01358877 2025-11-28

APHINITY

Phase 3 Completed

4,804 enrolled 45 charts 1 FDA

Breast Neoplasms

NCT07158164 2025-11-13

DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment

Phase 4 Recruiting

BreastGastrointestinalHead & Neck

Breast Neoplasms, Head and Neck Neoplasms, Colorectal Neoplasms

NCT02299999 2025-01-15

SAFIR02_Breast

Phase 2 Active not recruiting

Breast Neoplasms

NCT00798070 2024-12-18

PANTHER

Phase 3 Active not recruiting

Breast Neoplasms, Neoplasms

NCT02897700 2024-04-17

COC-IDCB

Phase 1 Recruiting

Breast Neoplasms

NCT01996267 2024-03-29

TRAIN-2

Phase 3 Active not recruiting

Breast Neoplasms

NCT00036868 2024-03-08

Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT00630032 2024-02-21

TavIx

Phase 3 Completed

762 enrolled 14 charts

Breast Neoplasms

NCT00525759 2023-11-24

ANZAC

Phase 2 Completed

Breast Neoplasms

NCT00309478 2023-06-29

Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients

Phase 3 Completed

Breast Neoplasms

NCT00121992 2023-04-04

Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment

Phase 3 Completed

1,060 enrolled 20 charts

Breast Neoplasms

NCT01036087 2023-03-30

Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

Phase 2 Completed

47 enrolled 13 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00129389 2023-03-07

FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients

Phase 3 Completed

1,925 enrolled 19 charts

Breast Neoplasms

NCT00129922 2023-03-06

Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00773695 2023-01-09

A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT01779050 2022-11-01

Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells

Phase 2 Terminated

7 enrolled 8 charts

Breast Neoplasms

NCT00087178 2022-08-11

Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer

Phase 3 Completed

2,722 enrolled 14 charts

Breast Neoplasms

NCT01966471 2022-06-14

A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer

Phase 3 Completed

1,846 enrolled 19 charts

Breast Neoplasms

NCT02897050 2022-04-20

Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer

Phase 2 Suspended

Breast Neoplasms

NCT02742051 2021-09-23

A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT01593020 2021-09-22

Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2

Phase 2 Completed

54 enrolled 10 charts

Breast Neoplasms

NCT02132949 2021-09-17

BERENICE

Phase 2 Completed

401 enrolled 24 charts

Breast Neoplasms

NCT01220128 2021-05-25

INDUCT

Phase 2 Terminated

66 enrolled 40 charts

Breast Neoplasms

NCT00309569 2020-10-14

Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients

Phase 3 Completed

Breast Neoplasms

NCT00014222 2020-10-05

Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer

Phase 3 Completed

2,104 enrolled 11 charts

Breast Neoplasms

NCT00625898 2020-09-10

BETH

Phase 3 Terminated

Breast Neoplasms

NCT00003086 2020-07-14

Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer

Phase 1/2 Terminated

Breast Neoplasms

NCT00510367 2020-07-10

Primary Breast Cancer Occurring Concomitant With Pregnancy

Phase EARLY_PHASE1 Completed

Breast Neoplasms

NCT01803282 2020-06-02

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors

Phase 1 Completed

236 enrolled 21 charts

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04031703 2020-04-24

Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN)

Phase 3 Completed

Breast Neoplasms

NCT00002542 2020-04-01

Tamoxifen in Treating Women With High-Risk Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT02124148 2020-04-01

A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer

Phase 1 Completed

BreastGastrointestinal

Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

NCT00820547 2019-10-22

Beverly1

Phase 2 Completed

Breast Neoplasms, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

NCT02115204 2019-10-03

4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF

Phase 3 Completed

Breast Neoplasms

NCT02506777 2019-09-04

MBC1

Phase 2 Unknown

Breast Neoplasms

NCT02995772 2019-06-19

Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients

Phase 3 Completed

Breast Neoplasms

NCT03888677 2019-03-28

Dose-adjusted Adjuvant FEC Compared to Standard FEC for Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00015886 2018-08-13

Combination Chemotherapy in Treating Women With Breast Cancer That is Metastatic or Cannot be Treated With Surgery

Phase 2 Completed

Breast Neoplasms

NCT00301925 2018-08-08

TACT2

Phase 3 Unknown

Breast Neoplasms, Breast Neoplasms, Male

NCT00559845 2018-04-09

A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer

Phase 2 Completed

56 enrolled 10 charts

Breast Neoplasms

NCT00950300 2018-01-23

A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer

Phase 3 Completed

596 enrolled 31 charts 1 FDA

Breast Neoplasms

NCT03349177 2017-11-21

Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy

Phase 2/3 Unknown

Breast Neoplasms

NCT02980965 2017-11-13

Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT02001506 2017-08-29

Neo-shorter

Phase 3 Completed

Breast Neoplasms

NCT01222052 2017-06-26

NNBC3-Europe

Phase 3 Unknown

Breast Neoplasms